摘要
目的探索突发公共卫生事件中捐赠药品的管理问题,建立一套操作性较强的捐赠药品管理办法,以期为后续可能发生的类似事件提供借鉴和参考。方法查阅捐赠药品相关文献和管理办法,总结归纳其他医疗机构捐赠药品的管理模式及存在的问题,结合国家卫生健康委员会办公厅印发的新型冠状病毒肺炎(COVID-19)防控方案和我院发热门诊小组诊疗方案,制定我院COVID-19捐赠药品遴选目录和管理办法,指导我院捐赠药品的管理工作。结果初步建立了一套操作性较强的捐赠药品管理办法,包括成立并完善COVID-19捐赠药品管理小组,制定捐赠药品遴选目录,捐赠药品接收和资质验证,捐赠药品的存储、发放和使用,捐赠药品账务管理和公示,部分剩余捐赠药品的处理。捐赠药品总使用率为86.64%。结论突发公共卫生事件中医院药学人员通过实践积累了大量捐赠药品的管理经验,并提出了一些较好的管理策略,捐赠药品遴选使用指南的制定以及捐赠药品管理工作的信息化和体系化建设有待进一步加强和推进。
Objective This paper explores the management of donated drugs in public health emergencies,and establishes a set of operational management methods for donated drugs,so as to provide reference for the following similar events.Methods Review the relevant literature and management methods of donated drugs,summarize the management models and problems of donated drugs in other medical institutions,and formulate the selection list and management methods of donated medicines for New Crown Pneumonia to guide the donated medicines management work in our hospital by referring the new coronavirus pneumonia prevention and control program issued by the General Office of the National Health and Health Commission and our hospital's outpatient diagnosis and treatment program.Results A set of operational management measures for donated drugs was established,It includes the establishment and improvement of covid-19 donation drug management team,the development of donation drug selection catalog,donation drug receiving and qualification verification,the storage,distribution and use of donated drugs,donation drug accounting management and publicity,and the treatment of some remaining donated drugs.The total utilization rate of donated drugs was 86.64%.Conclusion In public health emergencies,Chinese pharmacists have accumulated a lot of experience in the management of donated drugs,and put forward some good management strategies.The development of guidelines for the selection and use of donated drugs and the informatization and systematization of the management of donated drugs need to be further strengthened and promoted.
作者
邱志国
邓斌
吕永宁
张玉
罗立
QIU Zhiguo;DENG Bin;Lü Yongning;ZHANG Yu;LUO Li(Department of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,Wuhan 430022,China)
出处
《药物评价研究》
CAS
2020年第6期1003-1007,共5页
Drug Evaluation Research
基金
国家重点研发计划资助项目(2017YFC0909900)。
